PD-1 Blockage Facilitates Cytotoxic T and NK Cells Tumoricidal Phenotype in a Murine Breast Carcinoma

1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. Search in Google Scholar

2 Internet site: https://gco.iarc.fr/today/data/factsheets/populations/688-serbia-fact-sheets.pdf Search in Google Scholar

3 Brown L, Carr MJ, Sam C, Sun W, Whiting J, Kim Y, et al. Tolerance and Outcomes of Neoadjuvant Chemotherapy in Geriatric Breast Cancer Patients. J Surg Res. 2023; 283: 329-335. doi:10.1016/j.jss.2022.10.092. Search in Google Scholar

4 Guo YQ, Ju QM, You M, Liu Y, Yusuf A, Soon LK. Depression, anxiety and stress among metastatic breast cancer patients on chemotherapy in China. 2023; 22(1): 33. doi: 10.1186/s12912-023-01184-1. Search in Google Scholar

5 Wang J, Seebacher N, Shi H, Kan Q, Duan Z. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget. 2017; 8(48): 84559-71. doi: 10.18632/oncotarget.19187. Search in Google Scholar

6 Hu Y, Li Y, Yao Z, Huang F, Cai H, Liu H, et al. Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer. Cancers (Basel). 2023; 15(3): 563. doi: 10.3390/cancers15030563. Search in Google Scholar

7 Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359: 1350-1355. doi: 10.1126/science.aar4060. Search in Google Scholar

8 Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11): 3887-95. doi: 10.1002/j.1460-2075.1992.tb05481.x. Search in Google Scholar

9 Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F, et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology. 2018; 8(3): 1557030. doi: 10.1080/2162402X.2018.1557030. Search in Google Scholar

10 Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol. 2017; 139 (1): 335-346.e3. doi: 10.1016/j.jaci.2016.04.025. Search in Google Scholar

11 Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, et al. Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy. Clinics (Sao Paulo). 2023; 78: 100177. doi: 10.1016/j.clinsp.2023.100177. Search in Google Scholar

12 Nie X, Chen W, Zhu Y, Huang B, Yu W, Wu Z, et al. B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb. Cell Mol Immunol. 2018; 15(10): 888-97. doi: 10.1038/cmi.2017.17. Search in Google Scholar

13 Hoffmann O, Wormland S, Bittner AK, Collenburg M, Horn PA, Kimmig R, et al. Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse. J Cancer Res Clin Oncol. 2023; 149(3):1159-74. doi: 10.1007/s00432-022-039 80-9. Search in Google Scholar

14 Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015; 21 (1): 24-33. Search in Google Scholar

15 Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel). 2020; 12 (3): 738. Search in Google Scholar

16 Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016; 44 (5): 955-72. Search in Google Scholar

17 Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018; 18 (10): 635-47. Search in Google Scholar

18 Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019; 234 (6): 8509-21. Search in Google Scholar

19 Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends Immunol. 2019; 40 (4): 310-27 Search in Google Scholar

20 Alper KM, Gunes E. The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev. 2016; 31: 73-81. Search in Google Scholar

21 Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. 2016; 1(17): e89829. doi: 10.1172/jci.insight.89829. Search in Google Scholar

22 Davis ZB, Vallera DA, Miller JS, Felices M. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol. 2017; 31: 64-75. doi:10.1016/j.smim.2017.07.011. Search in Google Scholar

23 Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity. 2017; 47(5): 820-33. doi: 10.1016/j.immuni.2017.10.008. Search in Google Scholar

24 Jurisevic M, Jagic N, Gajovic N, Arsenijevic A, Jovanovic M, Milovanovic M, et al. O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl) propanoate dihydrochloride enhances influx of effective NK and NKT cells in murine breast cancer. Vojnosanit Pregl. 2020; 77(7): 715–723 doi:10.2298/VSP180723149J. Search in Google Scholar

25 Gajovic N, Jurisevic M, Pantic J, Radosavljevic G, Arsenijevic N, Lukic ML, et al. Attenuation of NK cells facilitates mammary tumor growth in streptozotocin-induced diabetes in mice. Endocr Relat Cancer 2018; 25(4): 493-507. Search in Google Scholar

26 Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2020; 18(4): 479-489. doi: 10.6004/jnccn.2020.7554. Search in Google Scholar

27 Liu Q, Cheng R, Kong X, Wang Z, Fang Y, Wang J. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. Front Immunol. 2020; 11: 558757. doi: 10.3389/fimmu. 2020.558757. Search in Google Scholar

28 Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, et al. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. Cancer Discov. 2019; 9(10): 1422-1437. doi: 10.1158/2159-8290.CD-18-1259. Search in Google Scholar

29 Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, et al. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest. 2020; 130(3): 1185-1198. doi: 10.1172/JCI128895. Search in Google Scholar

30 Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, et al. CD56^brightCD16⁻ NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4⁺ T cell proliferation. J Immunol. 2015; 195(3): 965–972. doi: 10.4049/jimmunol.1500591. Search in Google Scholar

31 Tian W, Wang L, Yuan L, Duan W, Zhao W, Wang S, et al. A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6. Cancer Sci. 2016; 107(7): 882–889. doi: 10.1111/cas.12964. Search in Google Scholar

32 Zwirner NW, Domaica CI, Fuertes MB. Regulatory functions of NK cells during infections and cancer. J Leukoc Biol. 2021; 109(1): 185-194. doi: 10.1002/JLB.3MR0820-685R. Search in Google Scholar

33 Zhang H, Li Y, Liu X, Liang Z, Yan M, Liu Q, et al. ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression. Immunology. 2018; 155(2): 238-250. doi: 10.1111/imm.12954. Search in Google Scholar

34 Wu D, Liu Y, Pang N, Sun M, Wang X, Haridia Y, et al. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients. Medicine (Baltimore). 2019; 98(43): e17608. doi: 10.1097/MD.000000 0000017608. Search in Google Scholar

35 Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019; 178(5): 1189-1204.e23. doi: 10.1016/j.cell.2019.07.044. Search in Google Scholar

36 Amatya N, Garg AV, Gaffen SL. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 2017; 38(5): 310- 322. doi: 10.1016/j.it.2017.01.006. Search in Google Scholar

37 Borrego F, Robertson MJ, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999; 97(1): 159–165. Search in Google Scholar

38 Wang Z, Tan F. The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19+ CD25+ Bregs and suppresses the secretion of IL-10 in patients with allergic rhinitis. Scand J Immunol. 2020; 91(2): e12836. doi: 10.1111/sji.12836. Search in Google Scholar

39 Prasad S, Hu S, Sheng WS, Chauhan P, Lokensgard JR. Reactive glia promote development of CD103+ CD69+ CD8+ T-cells through programmed cell death-ligand 1 (PD-L1). Immun Inflamm Dis. 2018; 6(2): 332-344. doi: 10.1002/iid3.221. Search in Google Scholar

40 Gao Z, Feng Y, Xu J, Liang J. T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. Front Immunol. 2022; 13: 977394. doi: 10.3389/fimmu.2022.977394. Search in Google Scholar